Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The researchers report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA).

Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children.

Who Took Part

The abstract describes 139 children taking part.

The age groups tagged for this paper are young children and children, both men and women.

A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively.

Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr.

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2-8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score.

The subject headings attached to it are Body Height, Europe, Growth, Human Growth Hormone, Infant, Small for Gestational Age, Longitudinal Studies and Puberty.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 139 children.

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.